For the year ending 2025-12-31, TNGX made $62,384K in revenue. -$101,706K in net income. Net profit margin of -163.03%.
| Income Statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total revenue | 62,384 | 42,069 | 36,527 | 24,860 |
| Research and development | 132,165 | 143,918 | 115,198 | 105,906 |
| General and administrative | 41,508 | 43,746 | 35,502 | 30,025 |
| Total operating expenses | 173,673 | 187,664 | 150,700 | 135,931 |
| Loss from operations | -111,289 | -145,595 | -114,173 | -111,071 |
| Interest income | 5,630 | 7,890 | 6,619 | 1,456 |
| Other income, net | 4,069 | 7,611 | 5,944 | 1,493 |
| Total other income, net | 9,699 | 15,501 | 12,563 | 2,949 |
| Loss before income taxes | -101,590 | -130,094 | -101,610 | -108,122 |
| Provision for income taxes | 4 | 208 | 134 | 54 |
| Net loss | -101,594 | -130,302 | -101,744 | -108,176 |
| Unrealized (loss) gain on marketable securities | -112 | 150 | 3,891 | -2,940 |
| Comprehensive loss | -101,706 | -130,152 | -97,853 | -111,116 |
| Basic EPS | -0.87 | -1.19 | -1.08 | -1.23 |
| Diluted EPS | -0.87 | -1.19 | -1.08 | -1.23 |
| Basic Average Shares | 116,166,187 | 109,226,731 | 94,572,448 | 87,820,037 |
| Diluted Average Shares | 116,166,187 | 109,226,731 | 94,572,448 | 87,820,037 |
Tango Therapeutics, Inc. (TNGX)
Tango Therapeutics, Inc. (TNGX)